Fundraising Fox
Boston · Series B–Late Stage · 31 people tracked
Find your way into Bain Capital Life Sciences
Sign up to see every warm intro you have to Bain Capital Life Sciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bain Capital Life Sciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Bain Capital Life Sciences targets biopharmaceutical, medical device, diagnostic, and life science tool companies globally with a focus on addressing unmet medical needs. The team leverages extensive public and private investing expertise, operating and consulting experience, and deep scientific and medical knowledge to invest at scale and provide strategic support during critical value-creation phases. The firm pursues a science-first diligence approach to build a diverse portfolio of high-impact, value-creating companies in the life sciences sector.
Source: firm website, verified Sep 26, 2026.
Team · 31 people
from the firm's website & public directories
Amir Zamani is a Partner on the Life Sciences team at Bain Capital, which he joined in 2018. He was previously a Partner at McKinsey & Company, where he worked in the Biopharmaceutical and Medical Products Practice, and earlier was a resident in Plastic Surgery at the University of Pennsylvania. He earned his MD from The Johns Hopkins University School of Medicine and holds a BS in biological sciences and a BA in economics from Stanford University.
Andrew Hack is a Partner on the Life Sciences team at Bain Capital, which he joined in 2019. He previously served as Chief Financial Officer of Editas Medicine and as a portfolio manager at Millennium Management running a market-neutral healthcare hedge fund, and earlier worked as a securities analyst at healthcare-focused hedge funds and banks and as Director of Life Sciences at Reify Corporation. He holds an MD and PhD in molecular genetics and cell biology and an AB in biology, all from the University of Chicago.
Nicholas Downing is a Partner on the Life Sciences team at Bain Capital, which he joined in 2018. He previously was a resident physician at Brigham and Women's Hospital in Boston and worked as a consultant at McKinsey & Company, serving pharmaceutical, hospital, and financial services clients. He has authored more than 40 peer-reviewed articles and holds a chemistry degree from Harvard College and an MD from Yale University School of Medicine.
Ricky Sun is a Partner on Bain Capital's Life Sciences team, which he joined in 2016. Before Bain Capital, he was Director of Corporate Development and Strategy at Biogen, a Vice President at BlackRock, and a healthcare analyst at Citadel, Alyeska Investment Group, Lehman Brothers, and Morgan Stanley; he began his career as a senior scientist at Ironwood Pharmaceuticals. He holds a PhD in chemistry and chemical biology from Harvard, an MBA from NYU Stern, and a BA in chemistry from Berea College.
Adam M. Koppel is a Partner on the Life Sciences team at Bain Capital, which he first joined in 2003 and rejoined in 2016, having earlier been part of the firm's Public Equity team focused on healthcare. Between his stints at Bain Capital, he served as EVP of Corporate Development and Chief Strategy Officer at Biogen, and prior to that was an Associate Principal at McKinsey & Company. He holds an MD and PhD in neuroscience and an MBA from the University of Pennsylvania, and an AB and AM in history and science from Harvard University.
Evan Greif is a Principal on the Life Sciences team at Bain Capital, which he joined in 2020. Before that, he worked as an Analyst covering healthcare at Orbis Investments and as an Associate Consultant at Bain & Company. He holds a BA in applied mathematics and an MA in statistics from Harvard University, along with a MAST in pure mathematics from Cambridge University.
John Trzupek joined Bain Capital in 2025 as a Managing Director on the Life Sciences team. He previously served as COO and CFO at Abata Therapeutics and Chief Business Officer at KSQ Therapeutics, and held business and scientific roles at Pfizer, including Director of Strategy for inflammation and immunology. He began his career as a Research Fellow at Memorial Sloan-Kettering Cancer Center.
Lei Meng is a Managing Director on the Life Sciences team at Bain Capital, which she joined in 2024. She previously worked in therapeutics private investments at Avidity Partners and held roles in marketing analytics and business development at Allergan, as well as earlier positions at Merck & Co, Forest Labs, McKinsey & Company, and Samlyn Capital. She holds an MA in chemistry from Harvard University, an MBA from INSEAD, and a BA in biochemistry from Barnard College, Columbia University.
Leonard Feiner, MD, PhD, is a Principal on the Life Sciences team at Bain Capital, which he joined in 2021. Before that, he worked as a vitreoretinal surgeon and served as principal investigator on over 50 clinical trials covering conditions such as macular degeneration, diabetic macular edema, and retinal vein occlusion. He holds a degree in mechanical and aerospace engineering from Princeton University and an MD/PhD from the University of Pennsylvania, with an ophthalmology residency at Penn and a surgical retina fellowship at Washington University in St. Louis.
Matthew Calistri is a Managing Director in the Portfolio Group of Bain Capital's Life Sciences business, which he joined in 2024. He previously spent four years at Cerevel Therapeutics, serving as VP of Investor Relations and VP of Corporate Strategy, and held investor relations roles at Sage and Biogen. Earlier in his career he worked in financial services at Gerson Lehrman Group, ITG, UBS, Bankers Trust, and E&Y, and he holds an MBA in finance from the University of Chicago Booth School of Business and a BS in accounting from Fordham University.
Renjie Wang is a Managing Director on the Life Sciences team at Bain Capital, which she joined in 2014. She previously worked at Hony Capital, where she closed buyout, minority investment, and privatization transactions in the healthcare sector. She holds a master of finance from Peking University and a BA in economics from Fudan University.
Will Cozean is a Managing Director on Bain Capital's Life Sciences team, which he joined in 2013. He previously worked on the firm's North America Private Equity team in the Healthcare vertical, as well as its Industrial and Technology verticals, and earlier was a consultant at McKinsey & Company in Atlanta. He holds an MBA from Harvard Business School (Baker Scholar) and a BS in commerce from the University of Virginia (Jefferson Scholar).
Drew Field is a Principal on the Life Sciences team at Bain Capital, which he joined in 2020. Before that, he was a management consultant at Bain & Company in New York, working with healthcare and private equity clients, and previously held commercial strategy and investor relations roles at a biotech company. He holds a BA in biology and economics from Dartmouth College.
Jonah Cashdan is a Principal on the Life Sciences team at Bain Capital, which he joined in 2018. He previously worked in J.P. Morgan's healthcare investment banking group on M&A and financings for pharmaceutical, biotech, and medtech clients, and earlier studied synaptic physiology and sensory system development in labs at Georgetown University. He holds a BS in Neurobiology from Georgetown University.
Alyson Goff joined Bain Capital in 2025 as an Associate in the Portfolio Group for the Life Sciences business. Before that, she worked as a management consultant at Guidehouse in Boston, advising life-science sector clients on strategic initiatives. She holds an MS in biotechnology enterprise and entrepreneurship from Johns Hopkins University and a BA in biology from Boston University.
Amarilice Young joined Bain Capital in 2025 as Associate General Counsel for Life Sciences. She was previously a partner in the Life Sciences group at Goodwin Procter LLP. She holds a JD from University of Pennsylvania Law School and a BA in American Studies from Cornell University, and is a member of the Massachusetts and New York state bars.
Chiaka Ibe is an Associate on the Bain Capital Life Sciences team, which she joined in 2024. She was previously a management consultant at Bain & Company, advising clients in the Private Equity Group and Healthcare & Life Sciences practice, and worked as an analyst on the Health & Life Sciences team at Gates Ventures. She holds a BA in international health and human biology from Brown University.
Daniyal Sachee is an Associate on the Life Sciences team at Bain Capital, which he joined in 2025. He previously worked in the healthcare investment banking group at Goldman Sachs, advising on M&A, debt and equity financings, and royalty monetizations across the biotech and pharmaceutical sectors, and earlier conducted research on rare epilepsy-related disorders at Boston Children's Hospital. He holds a BA in Computational Neuroscience from Harvard.
Greg Koskinas is Chief Financial Officer for the Life Sciences business at Bain Capital, which he first joined in 2000 and rejoined in 2024. He was an original member of the firm's Absolute Return Capital business, overseeing trading and operational functions, and earlier worked in the finance group of the Public Equity business. Before returning to Bain Capital, he served as Chief Operating Officer and Chief Compliance Officer at ThornTree Capital Partners. He holds a BA in business and economics from Lafayette College.
Isaac Cheng is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2024. He previously held business development and strategy roles in the pharmaceuticals unit at Johnson & Johnson, and evaluated business development and licensing opportunities across pharmaceuticals, MedTech, and services at AbbVie (via its acquisition of Allergan). He began his life sciences career as a management consultant at ZS Associates.
Jay Corrigan is a Partner and Group Chief Financial Officer for Private Markets at Bain Capital, which he joined in 1996. He oversees the finance teams across the firm's Private Equity, Venture, Crypto, Double Impact, Life Sciences, Tech Opportunities, and Real Estate businesses, and also serves as CFO for Double Impact. Before Bain Capital he worked for three years at Ernst & Young, and he holds a BS in accounting from Fordham University.
Jennie Daisak is a Vice President on the Life Sciences team at Bain Capital, which she joined in 2021. Before Bain Capital, she worked in J.P. Morgan's healthcare investment banking group, advising biotechnology and pharmaceutical clients on M&A and debt/equity financings. She graduated from the University of Pennsylvania's Vagelos Program in Life Sciences & Management, earning a BA in biology and a BS in economics from the Wharton School with a finance concentration.
Kristen Deftos is a Partner and Head of Human Resources at Bain Capital, where she has worked since 2012, overseeing talent acquisition, performance management, and organizational development across the Double Impact, Life Sciences, Real Estate, and Tech Opportunities teams. Before Bain Capital, she held HR relationship management and global talent acquisition roles at Wellington Management Company and earlier worked in HR and recruiting at J.P. Morgan. She holds an AB from Bowdoin College and an MA in organizational psychology from Columbia University Teachers' College.
Melaku Arega is a Vice President on Bain Capital's Life Sciences team, which he joined in 2022. Before that, he was a medical student at Harvard Medical School, receiving clinical training at Beth Israel Medical Center and other Harvard-affiliated hospitals, and conducted research on cancer care disparities. He holds an MD from Harvard Medical School, an MBA from Harvard Business School, and a BS in neuroscience and molecular & cellular biology from Johns Hopkins University.
Molly Lawrence joined Bain Capital in 2025 as a Vice President of Human Resources, where she leads recruiting, development, and engagement efforts for the Life Sciences team. She previously served as Vice President of Talent Management and Development at Audax Private Equity and held talent roles at Bain & Company. She holds a BA from Dartmouth College.
Sharad Goyal is Senior Vice President and Head of IT for Private Markets at Bain Capital, which he joined in 2007. Before Bain Capital, he held technology consulting roles in the Global Capital Markets division of Sapient (now Publicis.Sapient). He holds an MBA in finance from Management Development Institute in India, along with a master's in computer science and a bachelor's in finance.
Shuvam Chaudhuri is an Associate on the Life Sciences team at Bain Capital, which he joined in 2023, having previously served as a Life Sciences Fellow. He completed his doctoral research at Northwestern University, studying transcriptional mechanisms of immune cell differentiation in cancer, infection, and autoimmunity, and earlier worked in antiviral drug discovery at Janssen Research and Development.
Michael Cooney is a Vice President on the Life Sciences team at Bain Capital, which he joined in 2021 after serving as a Life Sciences fellow. Before Bain Capital, he was a graduate student researcher in the Department of Genetics at Harvard Medical School, focusing on genomic instability and epigenetic dysfunction in aging, and earlier worked at Genocea Biosciences on pre-clinical and clinical research into T-cell-inducing vaccines. He holds a PhD in biological and biomedical sciences from Harvard University and BS degrees in biology and biotechnology from Tufts University.
Founder mafia
2 people who came through Bain Capital Life Sciences went on to found or lead other companies.
What they invest in
from 89 of 114 portfolio companiesBiotech ×68Healthtech ×57Medical Devices ×33Digital Health ×12AI & Machine Learning ×8Deep Tech ×6Enterprise Software ×4Fintech ×4
HQs:United States×63Germany×2Switzerland×1United Kingdom×1Hong Kong×1Ireland×1
Who they back
founder profiles across 32 portfolio companiesFounding team size:solo founder×152 founders×143 founders×24+ founders×1
Where their founders studiedfrom 18 founders with education data
University of California, Berkeley ×3Harvard Business School ×2Massachusetts Institute of Technology ×2
What their founders studiedfrom 19 founders with field-of-study data
Life Sciences ×5Engineering ×4Business & Management ×3Chemistry ×3Economics ×2
Where their founders worked beforefrom 22 founders with career history
Atlas Venture ×2
6 founders hold a PhD · 3 hold an MBA (of 20 with degree data)
Investments · 114 tracked
founders shown can be your intro pathBy year:2026 · 72025 · 52024 · 22022 · 62021 · 82020 · 62019 · 42017 · 12016 · 12015 · 242 dated
Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.
BiotechHealthtechCharlestown, US
Ilan Ganot(Co-Founder and Director)inStephen DiPalma(Executive Officer)Carl Morris(Executive Officer)inAlexander Cumbo(President, Chief Executive Officer and Director)Martin Freed(Director)inPaul Herizch(Executive Officer)
Board seatAdam M. Koppel· per SEC Form D
Co-investorsForesite CapitalRA CapitalBain Capital
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Board seatAndrew Hack· per SEC Form D
Co-investorsBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA CapitalRiverVest Venture Partners+9 more
A Place for Mom is a senior care referral service that helps families find and compare senior living and care options, including assisted living, memory care, independent living, home care, nursing homes, and senior apartments.
ConsumerDigital HealthHealthtechMarketplacesWellness & FitnessVernon Hills, US
Douglas Hirsch(Director)Trevor Bezdek(Co-Chairman & Director)Jonathan Stevens(Executive Officer)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)Dennis Berger(Executive Officer)
Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBattery VenturesBessemer Venture PartnersBlue Sea CapitalBosch Ventures+38 more
Alkermes develops pharmaceutical medicines for psychiatric and neurological disorders, including addiction, serious mental illness, and sleep disorders.
BiotechHealthtechMedical Devices
Richard F. Pops(Chairman of the Board, former CEO)Joshua Reed(Senior Vice President, Chief Financial Officer)inBlair C. Jackson(President & Chief Executive Officer)inDavid J. Gaffin(Executive Vice President, Chief Legal Officer and Chief Compliance Officer; Secretary)inCraig C. Hopkinson(Executive Vice President, Research and Development and Chief Medical Officer)C. Todd Nichols(Senior Vice President, Chief Commercial Officer)in
Co-investorsCardinal PartnersVedanta CapitalHatteras Venture Partners
Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs.
BiotechHealthtechCambridge, US
Justin Klee(Director)inJoshua Cohen(Founder)in
BoardStephen D. Chubb(Director)George M. Milne, PH.D.(Director)
Co-investorsAlpha Wave GlobalALS Investment FundAvoro Capital Advisors
Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.
BiotechHealthtechMedical DevicesWestlake Village, US
Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)Ricky Sun(Director)
BoardPatrick Heron(Director)inDaniel Estes(Director)inJonathan Silverstein(Director)
Co-investorsFrazier Life SciencesRA Capital
Atea is a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies for single-stranded RNA viruses, currently focused on a bemnifosbuvir and ruzasvir regimen in Phase 3 development for hepatitis C virus (HCV).
BiotechHealthtechBoston, US
Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Jean-Pierre Sommadossi(President, CEO and Chairman of the Board)inAndrea Corcoran(Chief Financial Officer, Executive Vice President, Legal, and Secretary)Janet Hammond(Chief Development Officer)inMaria Arantxa Horga(Chief Medical Officer)inJohn Vavricka(Chief Commercial Officer)in
Co-investorsATEM Capital FundRA Capital
C4 Therapeutics develops targeted protein degradation medicines aimed at treating disease.
BiotechCambridge, US
Kenneth C. Anderson(Director)Andrew J. Hirsch(President and Chief Executive Officer)in
BoardMarc Cohen(Executive Officer, Director)inJason Fisherman(Executive Officer, Director)Miles Stuchin(Director)Bruce Downey(Director)
Co-investors3E Bioventures CapitalNextech InvestRA CapitalRoche Venture FundCobro Ventures
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases.
BiotechHealthtechRadnor, US
Steven Nichtberger(Founder)inDan Geffken(Executive Officer)inAnup Marda(Chief Financial Officer)inMark Simon(Director)
BoardBrian Daniels(Director)in
Co-investors5AM VenturesDeerfield Management Company
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAccess BiotechnologyAtlas VentureForesite CapitalFrazier Life SciencesOrbiMed5AM Ventures+7 more
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+15 more
Heartflow provides an AI-based analysis that converts a coronary CTA scan into a personalized 3D model of the heart, assessing anatomy and physiology to help diagnose and manage coronary artery disease (CAD).
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesRedwood City, US
Christopher K. Zarins(Executive Officer, Director)inCharles A. Taylor(Executive Officer, Director)inNicky Espinosa Hayes(Executive Officer)John Stevens(Executive Officer, Director)inH. Baird Radford, III(Executive Officer)John Farquhar(President, Chief Executive Officer & Director)in
Co-investors3Spoke CapitalBlue Venture FundsEmergent Medical Partners, LLPKhosla VenturesLifeforce CapitalLotus Capital+3 more
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)in
Co-investorsForesite CapitalGV (Google Ventures)MRL Ventures FundPremji InvestRA CapitalFidelity Investments+6 more
Kestra Medical Technologies develops wearable medical devices and digital healthcare solutions designed for collaborative care between providers and patients.
Digital HealthHardwareHealthtechMedical Devices
Brian Webster(President, Chief Executive Officer, and Director)inTraci S. Umberger(General Counsel, Chief Administrative Officer, and Director)inVaseem Mahboob(Chief Financial Officer)inAl Ford(Chief Commercial Officer)inTimothy Moran(Chief Business Officer)
Co-investorsAndera PartnersLongitude CapitalStar51 CapitalBain Capital
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBessemer Venture PartnersHatteras Venture PartnersMRL Ventures FundNextech Invest+7 more
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsVida VenturesWestlake Village BioPartnersGilead SciencesInsight PartnersKleiner PerkinsNorthpond Ventures+3 more
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.
BiotechDigital HealthHealthtechMedical Devices
Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)
Co-investorsCheyenne VenturesClaremont Creek VenturesForesite CapitalHarmony PartnersHBM Healthcare InvestmentsLightspeed Venture Partners+4 more
Olema is a clinical-stage biopharmaceutical company developing novel therapies for metastatic breast cancer and other endocrine-driven cancers, targeting nuclear receptors and mechanisms of acquired resistance.
BiotechHealthtechSan Francisco, US
Cyrus L. Harmon, Ph.D.(Director)Cyrus L. Harmon(Director)inDavid C. Myles, Ph.D.(Executive Officer)Sean Bohen, M.D., Ph.D.(Executive Officer, Director)Naseem Zojwalla, M.D.(Executive Officer)inShane Kovacs(Executive Officer)in
Co-investorsAvoro Capital AdvisorsForesite CapitalLightspeed Venture PartnersRA CapitalWellington ManagementBiotechnology Value Fund+2 more
Replimune is a biotech company developing oncolytic immunotherapies designed to activate immune responses against difficult-to-treat cancers.
BiotechHealthtechMedical Devices
Robert Coffin(Founder and Chief Scientist)Sushil Patel(Chief Executive Officer)Emily Hill(Chief Financial Officer)Konstantinos Xynos(Chief Medical Officer)
Co-investorsAtlas VentureForesite CapitalREDMILE
Revolution Medicines is a biopharmaceutical company focused on discovering and developing medicines using its proprietary Tri-Complex Platform and RAS(ON) Biology research approach.
BiotechHealthtechMedical DevicesRedwood City, US
Margaret Horn(Executive Officer)Mark A. Goldsmith(Executive Officer, Director)inJack Anders(Chief Financial Officer)Stephen M. Kelsey(President, Research and Development)Alan Sandler(Chief Development Officer)inAnthony Mancini(Chief Global Commercialization Officer)
Co-investorsForesite CapitalGen CapitalGV (Google Ventures)Illinois VenturesNextech InvestThe Column Group+2 more
Savara is a biopharmaceutical company developing treatments for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and other rare lung diseases.
BiotechHealthtechMedical DevicesAustin, US
Matt Pauls(Chair of the Board of Directors and Chief Executive Officer)inMike Ciesla(Executive Officer)Badrul Chowdhury(Executive Officer)inSantosh J. Vetticaden(Executive Officer)Gregory D. Gorgas(Executive Officer)Patrick Keran(Executive Officer)
Co-investorsCentral Texas Angel NetworkGreen Park & Golf VenturesKeiretsu ForumMoore Venture PartnersNew Enterprise Associates (NEA)
Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.
BiotechHealthtechMedical Devices
Bobak Azamian(Founder)inJeffrey Farrow(Chief Financial Officer and Chief Strategy Officer)Seshadri Neervannan(Chief Operating Officer)Aziz Mottiwala(Chief Commercial Officer)inDianne Whitfield(Chief Human Resources Officer)inElizabeth Yeu-Lin(Chief Medical Officer)
Co-investorsAPERTURE Venture PartnersFlying L PartnersFrazier Life SciencesVisionary VenturesVivo CapitalRTW Investments L.P.
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyDecheng CapitalHBM Healthcare InvestmentsHBM Partners+5 more
X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.
BiotechBoston, US
Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in
Co-investorsLumira VenturesNew Enterprise Associates (NEA)Partners ResoluteThynk CapitalAdvent Life SciencesOmega Funds+1 more
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham VenturesREDMILE+9 more
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical DevicesSan Diego, US
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in
Co-investorsOrbiMedSR One Capital ManagementLilly Asia VenturesT. Rowe PriceAscenta CapitalTCG Crossover+3 more
Merida is a biotherapeutics company developing a new class of drugs designed to selectively and durably eliminate the pathogenic antibodies that drive autoimmune and allergic diseases.
BiotechHealthtech
Pierre Bruhns(Co-founder; Director of Research, Pasteur Institute)Mark Shlomchik(Co-founder; Professor of Immunology, University of Pittsburgh)Michael Naill(Senior Vice President, Process and Product Development)in
Co-investorsThird Rock VenturesGV (Google Ventures)Biotechnology Value FundThe Engine Ventures
Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia.
BiotechHealthtechMedical DevicesBaar, CH
Co-investorsHBM PartnersSK Capital PartnersMérieux Equity PartnersHBM Healthcare Investments
Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology.
BiotechMedical DevicesCambridge, US
Richard Malley(Director)inKamran Tavangar(Executive Officer)Steven Brugger(Executive Officer, Director)in
BoardRobert More(Director)Frances Heller(Director)George Siber(Director)
Board seatAndrew Hack· per SEC Form D
Co-investorsEcoR1 CapitalForesite CapitalViking GlobalBain CapitalRock Springs CapitalT. Rowe Price
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Board seatAdam M. Koppel· per SEC Form D
Co-investorsFrazier Life SciencesLatterell Venture PartnersLongitude CapitalOUP (Osage University Partners)Agent CapitalBain Capital+3 more
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Founder)in
BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)
Board seatAdam M. Koppel· per SEC Form D
Co-investorsARCH Venture PartnersGV (Google Ventures)Solas BioVenturesViking GlobalAccess BiotechnologyMaverick Capital+3 more
Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.
HealthtechMedical DevicesCampbell, US
Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in
BoardJames Rogers(Director)Stacy Enxing Seng(Director)
Board seatAndrew Hack· per SEC Form D
Co-investorsAscension VenturesCatalio Capital Management, LPDelos CapitalFemHealth VenturesLightstone Ventures
JenaValve develops transcatheter aortic valve replacement systems to treat severe aortic regurgitation and aortic stenosis.
Digital HealthHealthtechMedical DevicesIrvine, US
Hans Figulla(Director)Markus FerrariVictoria Carr-Brendel(Executive Officer, Director)David Drachman(Executive Officer, Director)John Kilcoynein
.jpg)
BoardArnd Kaltofen(Director)in
Board seatAndrew Hack· per SEC Form D
Co-investorsAndera PartnersRosetta Capital Ltd.VI PartnersAtlas VentureGimvInnovatus Capital Partners+5 more
Nuvalent is a biopharmaceutical company focused on structure-based drug discovery and the development of precision oncology therapies.
BiotechHealthtechMedical DevicesCambridge, US
Matthew Shair(Director)inHenry Pelish, PhD(Chief Scientific Officer)R. Porter James(Executive Officer, Director)inJames Porter, PhD(Chief Executive Officer)Alex Balcom(Chief Financial Officer)inChristopher Turner, MD(Chief Medical Officer)
Board seatAndrew Hack· per SEC Form D
Co-investorsAvoro Capital AdvisorsDeerfield Management CompanyViking GlobalWellington Management
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Co-investorsCatalio Capital Management, LPProto AxiomSanofi VenturesSV Health InvestorsTenmileAbingworth+2 more
Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtech
Co-investorsRA CapitalSofinnova VenturesAtlas VentureForbion
Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Carlos Quezada-Ruiz(Chief Medical Officer)in
Co-investorsSofinnova VenturesTCG CrossoverWellington Management
Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.
BiotechSouth San Francisco, US
Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)
Co-investorsFrazier Life SciencesLongitude CapitalViking GlobalBlackRockCasdin CapitalFranklin Templeton+6 more
Annexon is a clinical-stage biopharmaceutical company developing C1q and classical complement pathway inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.
BiotechHealthtechMedical DevicesSo. San Francisco, US
Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)
Co-investorsCorrelation VenturesNew Enterprise Associates (NEA)BlackRockBlackstone Life SciencesClarus VenturesDeerfield Management Company+2 more
Bain Capital is a private investment firm founded in 1984 that invests in and partners with companies to drive growth and improvement.
Sector AgnosticBoston, US
Co-investorsBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesBCISDVAccelBain Capital+2 more
Bain Capital Credit is an investment firm specializing in credit strategies including liquid and structured credit, leveraged loans, high-yield bonds, CLOs, and direct lending to middle-market companies.
Fintech
Co-investorsBain CapitalBain Capital Double Impact Fund LPBain Capital Tech Opportunities
Bain Capital Private Equity is an investment firm operating a private equity portfolio, with an investor portal for account holders.
Boston, US
Co-investorsBain CapitalBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesTwo Bear Capital
Bain Capital Real Estate is an investment firm focused on acquiring and operating real estate assets in niche, difficult-to-access sectors driven by long-term economic and secular trends.
PropTechBoston, US
Co-investorsBain CapitalBain Capital Double Impact Fund LPBain Capital Tech Opportunities
Bain Capital Special Situations is a private investment firm that combines private equity, private credit, and asset-backed capital to source and structure specialized deals across asset classes.
FintechSector AgnosticHong Kong, HK
Co-investorsBain CapitalBain Capital Double Impact Fund LPBain Capital Tech OpportunitiesFidelity InvestmentsGallatin Point Capital
Bain Capital Double Impact is an investment firm established in 2015 that funds companies generating both competitive financial returns and measurable social or environmental impact, with focus areas spanning healthcare access, economic opportunity, and environmental sustainability.
EdTechHealthtechImpact & Social Good
Co-investorsBain CapitalBain Capital Tech OpportunitiesBlue Haven Initiative
Beeline provides vendor management system (VMS) software for managing contingent and external workforces, including staffing suppliers and shift-based labor.
Future of WorkHR TechSaaS
Co-investorsAcadian Ventures Management, Llc
Beeline Medicines is a biopharmaceutical company developing medicines for patients with serious diseases.
BiotechHealthtechMedical DevicesStamford, US
Dr. Badreddin Edris(President and Chief Operating Officer)Saqib Islam(Chief Executive Officer)inNathalie Franchimont(Chief Medical Officer)in
Co-investorsBain Capital
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)in
Co-investorsBain CapitalAscenta CapitalDelos CapitalDigitalis VenturesNew Enterprise Associates (NEA)Bain Capital Tech Opportunities+4 more
CereVasc is developing the eShunt System, a minimally invasive device intended to treat communicating hydrocephalus in children and adults as an alternative to invasive neurosurgical procedures.
BiotechHealthtechMedical DevicesAuburndale, US
Carl Heilman(Director)Daniel Levangie(Executive Officer, Director)inLeslie Teso-Lichtman(Executive Officer)inFrederick Callori(Director)Patrick Sullivan(Director)Aaron Levangie(Executive Officer)
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Co-investors5AM VenturesAisling CapitalFrazier Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more
BiotechCambridge, US
Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)
BoardMartin Murphy(Director)
Co-investorsLifeSci Venture PartnersCasdin CapitalVenrock Healthcare Capital Partners
Developing therapeutics targeting epigenetic regulators to modulate gene expression; acquired by MorphoSys in June 2021 for $1.7B.
BiotechHealthtechCambridge, US
Michael R. Cooper(Executive Officer)inJames E. Audia(Executive Officer)Keith Dionne(Executive Officer, Director)Matthias Jaffe(Executive Officer)Mark A. Goldsmith(Director)inTom Maniatis(Director)
Co-investorsAvoro Capital AdvisorsThe Column GroupVenrockThird Rock Ventures
A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.
BiotechDigital HealthHealthtech
Co-investorsAccess BiotechnologyRidgeback CapitalOxford Bioscience PartnersRA Capital
Dynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology.
BiotechHealthtechDüsseldorf, DE
Ryan Spencer(Chief Executive Officer)inDavid Novack(President and Chief Operating Officer)inRobert Janssen(Chief Medical Officer and Senior Vice President, Clinical Development)inKelly MacDonald(Chief Financial Officer)inJeff Coon(Chief Human Resources Officer)Donn Casale(Chief Commercial Officer)in
Co-investorsHealthCapSanderling Ventures
Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, with a lead investigational asset, ecopipam, a selective dopamine D1 receptor antagonist for pediatric Tourette syndrome.
BiotechDigital Health
Co-investorsParagon Biosciences LLCValor Equity PartnersFidelity Investments
Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome.
BiotechMedical Devices
Jeff Aronin(Founder)
Co-investorsParagon Biosciences LLCFidelity InvestmentsValor Equity Partners
FemTechHealthtechMedical DevicesRedwood City, US
Christopher Owens(Executive Officer, Director)Darrin Uecker(Executive Officer, Director)
BoardKen Haas(Director)Jonathan MacQuitty(Director)inMike Carusi(Director)inDoug Fisher(Director)
Co-investorsAmzak HealthEndeavour VisionFemHealth VenturesKaiser Permanente VenturesKluz VenturesLightstone Ventures+6 more
Chronus is a platform that connects employees for guided, AI-assisted conversations focused on career development, mentoring, community building, and change adoption in enterprise organizations.
AI & Machine LearningEnterprise SoftwareFuture of WorkHR TechSaaSNew York, US
Aaron Hurst(Founder)in
Co-investorsEmpire AngelsGaingelsSand Hill AngelsVoyager CapitalAlly Bridge GroupAmed Ventures+6 more
__Twitter.png)
InflaRx is a biopharmaceutical company developing therapeutics that target the complement system to treat inflammatory diseases.
BiotechHealthtechJena, DE
Renfeng Guo(Founder)in
Co-investorsRA Capital
Bain Capital Insurance is the dedicated insurance investing and solutions arm of Bain Capital, making investments across the insurance value chain and growth spectrum.
FintechInsurTech
Co-investorsBain CapitalBain Capital Double Impact Fund LPBain Capital Tech Opportunities
BiotechPhiladelphia, US
Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)Lori Forrest(Executive Officer)Leon Moulder, Jr.(Director)Benjamin Lund(Director)in
BoardTomas Kiselak(Director)
Co-investorsAgent CapitalDC Investment PartnersLongwood FundOUP (Osage University Partners)Pfizer Venture InvestmentsQuan Capital+3 more
Bain Capital is a private equity investment firm with a Tokyo office that provides capital and strategic support to Japanese mid-market and large enterprises pursuing growth, restructuring, and business succession.
Enterprise SoftwareTokyo, JP
Co-investorsBain CapitalBain Capital Double Impact Fund LPBain Capital Tech Opportunities
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.
AI & Machine LearningBiotechDeep TechAustin, US
Joanne Dove Kotz(Founder)inJoel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)
Co-investorsAvalon BioVenturesPfizer Venture InvestmentsRA CapitalPfizer VenturesPolaris PartnersVersant Ventures
Kailera develops obesity management medications, including GLP-1 and multi-agonist receptor peptides and small molecules, with a global development pipeline led by injectable and oral formulations of ribupatide.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureCatalio Capital Management, LP
Longeviti Neuro Solutions develops cranial implant platforms for complex brain surgery, including patient-specific and off-the-shelf implants that restore skull contour and enable real-time post-operative ultrasound imaging.
HealthtechMedical Devices
Jesse Christopher(CEO & Co-founder)in
Co-investorsMaryland TEDCOTEDCO
BiotechRadnor, US
Scott Braunstein, MD(Executive Officer, Director)Edward F. Smith(Executive Officer)Joe Hulihan, MD(Executive Officer)
BoardNicole Vitullo(Director)Enrique J. Carrazana, MD(Director)Michael R. Dougherty(Director)
Co-investorsAvoro Capital AdvisorsCanaan PartnersConnecticut InnovationsSofinnova VenturesDomain AssociatesFlare Capital Partners+1 more
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsF-Prime CapitalLightstone VenturesNew Enterprise Associates (NEA)Nextech InvestPfizer Venture InvestmentsRho Ventures+3 more
NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.
BiotechHealthtechMedical Devices
Co-investorsBioGeneration VenturesEQT Life SciencesFrazier Life SciencesForbion
Nimbus Engineering is a hardware company and online retailer developing energy transfer technology, including its patented Power Relay, a portable power outlet for home, office, and outdoor use.
CleantechDeep TechEnergyHardwareSan Francisco, US
Michael Gorman(Founder)in
Co-investorsFoothill VenturesAccess BiotechnologyAtlas VentureBiotechnology Value FundCommodore CapitalGV (Google Ventures)+2 more
FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.
AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US
Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)
Co-investorsPre-Seed to SucceedYellow Rocks!Access BiotechnologyAtlas VentureBiotechnology Value FundCommodore Capital+3 more
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAccess BiotechnologyAtlas VentureDementia Discovery FundGV (Google Ventures)Lightstone VenturesPfizer Venture Investments+4 more
Nurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US
Arthur T. Sands(Executive Officer, Director)inGwenn M. Hansen(Chief Scientific Officer)inTimothy Kutzkey(Executive Officer, Director)
BoardDavid Goeddel(Director)inMark Goldsmith(Director)
Co-investorsEcoR1 CapitalForesite CapitalGeneral AtlanticSofinnova VenturesThe Column GroupWellington Management+1 more
Octant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases.
AI & Machine LearningBiotechDeep TechMedical DevicesEmeryville, US
Sri Kosuri(Founder)inRamsey Homsany(Founder)inRobert Andrade(Executive Officer, Director, Promoter)Maurice J. Costantini(Executive Officer, Director, Promoter)
Co-investorsAndreessen Horowitz+ND Capital8VCCarbon SiliconCatalio Capital Management, LPExplorer Investments+10 more
Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.
BiotechHealthtech
Co-investorsForesite CapitalGeneral AtlanticKurma PartnersvenBio PartnersViking Global
Pillar Biosciences develops kitted next-generation sequencing (NGS) panels and its SLIMamp single-tube library preparation technology for clinical and research laboratories, focused on cancer diagnostics.
BiotechDigital HealthHealthtechMedical DevicesNatick, US
Shawn Liu(Director)Hui Yang(Director)Gang Song(Executive Officer, Director)Zhaohui Wang(Director)Robert Forrester(Director)inHong Fang Song(Director)
Co-investorsCatalio Capital Management, LPHB VenturesSoleus Capital
Riskgaming creates immersive strategy simulation games where high-level decision-makers assume roles and navigate complex scenarios involving technology, business, and geopolitical challenges to explore alternative outcomes and inform real-world decisions.
BiotechHayward, US
Kegan Schouwenburg(Executive Officer, Director)Roger M. Perlmutter(Executive Officer, Director)in
BoardJoshua Wolfe(Director)inDror Berman(Director)James Tananbaum(Director)Leon Chen(Director)
Co-investorsCisco InvestmentsForesite CapitalLux CapitalDimension Capital
Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.
BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US
Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)Allen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)inShaharyar Khan(Co-founder & Chief Scientific Officer)in
BoardFrancesco De Rubertis(Director)in
Co-investorsMedicxiLongitude CapitalRA Capital
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalThe Column GroupCanaan PartnersRA CapitalTCG CrossoverDeerfield Management Company+2 more
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing neuropsychiatric medicines based on mechanisms including muscarinic M1/M4 agonism and NMDA antagonism.
BiotechHealthtechMental Health
Co-investorsThird Rock VenturesGV (Google Ventures)
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Bain Capital Tech Opportunities is a technology-focused investment firm that provides growth capital, along with strategic and operational support, to entrepreneurs and management teams during expansion phases.
Enterprise SoftwareFintechSaaS
Co-investorsBain CapitalBain Capital Double Impact Fund LP
Tenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases.
BiotechMedical Devices
Tony Estrada(President & Chief Executive Officer; co-founder)in
Co-investorsARCH Venture PartnersF-Prime CapitalDigitalis VenturesForbionMubadala Capital
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases by acquiring drug assets against validated targets.
BiotechHealthtech
Transforming the lives of patients through a functional cure for Type 1 Diabetes
BiotechSan Diego, US
Brittany Bradrick(Executive Officer)Anne Sandan(Executive Officer)Elizabeth Bui(Executive Officer)Steve White(Executive Officer)Howard Foyt(Executive Officer)inKevin D'Amour(Executive Officer)in
Co-investorsArtis VenturesATEL VenturesRA CapitalSanderling VenturesThe Vertical GroupJohnson & Johnson Innovation – JJDC+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Cardurion Pharmaceuticals, Inc.AavantiBioAmylyx PharmaceuticalsAngitiaApreoArcutis BiotherapeuticsAtsenaAvistone PharmaceuticalsBridge TO LifeCaldera Therapeutics, Inc.Cerevel TherapeuticsCidaraDianthusEyeBioFISHugel PharmaOMass TherapeuticsRapid Micro BiosciencesReplimune GroupRiver RenalSeránSpringWorks TherapeuticsSyremisSyros PharmaceuticalsTanabe PharmaTenacia BiotechnologyThird Harmonic BioThrive Earlier DetectionTruvic Medical
Exits · 31
25 IPOs · 6 acquisitions · showing 29Solid BiosciencesNASDAQ: SLDBXilio TherapeuticsNASDAQ: XLOA Place for MomNASDAQ: GDRXAlkermesNASDAQ: ALKSAmylyxNASDAQ: AMLXArcutisNASDAQ: ARQTAtea PharmaceuticalsNASDAQ: AVIRC4 TherapeuticsNASDAQ: CCCCCabaletta BioNASDAQ: CABADisc MedicineNASDAQ: IRONFreenomeNASDAQ: FRNMHeartFlowNASDAQ: HTFLInvivydNASDAQ: IVVDKestra Medical TechnologiesNASDAQ: KMTSKymera TherapeuticsNASDAQ: KYMRKyverna TherapeuticsNASDAQ: KYTXNateraNASDAQ: NTRAOlema PharmaceuticalsNASDAQ: OLMAReplimuneNASDAQ: REPLRevolution MedicinesNASDAQ: RVMDSavaraNASDAQ: SVRATarsus PharmaceuticalsNASDAQ: TARSUpstream BioNASDAQ: UPBX4 PharmaNASDAQ: XFORConstellation Pharmaacq. by NovartisDynavaxacq. by SanofiEyeBioacq. by MerckGynesonicsacq. by HologicJnana Therapeuticsacq. by Otsuka
Portfolio news
latest coverage across their companies
Kyverna Therapeutics · biospace.com · Sep 3, 2026
Invivyd · investors.invivyd.com · Sep 1, 2026
Amylyx · biopharminternational.com · Aug 20, 2026
InflaRx · manilatimes.net · Aug 20, 2026
Abcuro · finsmes.com · Aug 18, 2026
Upstream Bio · stocktitan.net · Aug 11, 2026
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Fund IV. L.P.LPs: New Jersey Division of Investment, California Public Employees' Retirement System, Maryland State Retirement and Pension System | 2024 | — | — | 0.00x | 0.00x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Replimune | 9.2% | $15.00 | Jul 2018 | $42.6M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ4 insider ownership filings (Forms 3/4/5)
at Kailera Therapeutics, Inc. (KLRA), Olema Pharmaceuticals, Inc. (OLMA)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has Bain Capital Life Sciences made?
- Bain Capital Life Sciences has 114 tracked investments, 31 of which have exited, including 12 dated in the last 24 months.
- What stage does Bain Capital Life Sciences invest at?
- Bain Capital Life Sciences invests at the Series B, Series C, Growth, Late Stage stages.
- What sectors does Bain Capital Life Sciences focus on?
- Bain Capital Life Sciences focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Bain Capital Life Sciences located?
- Bain Capital Life Sciences is headquartered in Boston, US.
- Does Bain Capital Life Sciences lead rounds?
- Bain Capital Life Sciences has led 10 of the 22 rounds where its role is on record.
- Who does Bain Capital Life Sciences co-invest with?
- Bain Capital Life Sciences most often shares deals with RA Capital, Foresite Capital, Frazier Life Sciences, among 166 tracked co-investors.
- What size deals does Bain Capital Life Sciences back?
- Across 6 deals with disclosed amounts, Bain Capital Life Sciences has joined rounds of $100M – $250M (median $105M).
Co-investors · 11
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
Bain Capital is a global private investment firm operating across private equity, growth and venture, credit, real assets, and capital solutions, partnering with companies to create value across sectors and regions.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
General Atlantic is a global investment firm that partners with entrepreneurs and companies to build long-term value through growth equity, credit, energy transition, and infrastructure strategies.
ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.
Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel, differentiated therapeutics and treatments addressing unmet patient needs, from preclinical through commercial stages.
Novo Holdings is the investment arm of the Novo Nordisk Foundation and a leading life science investor that also manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity assets.
SV Angel is a San Francisco-based firm that invests long-term in founders, supporting them with advice, introductions, and network access at key business inflection points.
New Leaf Venture Partners is a venture capital firm investing in innovative healthcare companies.
Unknown Ventures is a venture studio based in Austin that provides funding and operational support to early-stage startups at the pre-seed to Series A stage. The firm backs founders seeking to create innovative solutions that improve human experience.
Triatomic Capital is an investment firm focused on 'century defining' themes across advanced technology areas including AI infrastructure, semiconductors, materials, robotics, and energy.
Firms observed investing alongside Bain Capital Life Sciences, from public investor directories. Shared companies are the overlap with Bain Capital Life Sciences's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.
Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.